Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFFN Diffusion Pharmaceuticals		$4.64	$2.76 ▼ $7.40	$8.98M	1.78	10,937 shs	351,000 shs
ELYM Eliem Therapeutics	$1.22 -2.4%	$1.25	$2.35 ▼ $11.55	$36.30M	-0.39	486,688 shs	114,913 shs
ONCY Oncolytics Biotech	$0.34 -6.7%	$0.52	$0.34 ▼ $1.53	$29.38M	1	573,527 shs	933,106 shs
RANI Rani Therapeutics	$0.56 -3.5%	$1.01	$0.46 ▼ $5.74	$32.14M	0.25	802,033 shs	135,895 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFFN Diffusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ELYM Eliem Therapeutics	+5.93%	+3.31%	-1.57%	-10.07%	-83.70%
ONCY Oncolytics Biotech	-2.96%	-9.33%	-38.44%	-44.85%	-66.57%
RANI Rani Therapeutics	-6.66%	-10.63%	-47.82%	-62.14%	-88.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	1.2155 of 5 stars	3.4	2.0	0.0	0.0	1.5	0.0	0.0
RANI Rani Therapeutics	2.2842 of 5 stars	3.6	1.0	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFFN Diffusion Pharmaceuticals	0.00	N/A	N/A	N/A
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	1,174.51% Upside
RANI Rani Therapeutics	3.20	Buy	$9.40	1,580.97% Upside

Current Analyst Ratings Breakdown

Latest DFFN, RANI, ELYM, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	$6.97 per share	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
RANI Rani Therapeutics	$1.20M	26.79	N/A	N/A	$0.51 per share	1.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFFN Diffusion Pharmaceuticals	-$15.59M	N/A	0.00	N/A	N/A	N/A	-69.96%	-62.98%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
ONCY Oncolytics Biotech	-$20.56M	-$0.29	N/A	N/A	N/A	N/A	-141.15%	-84.73%	7/30/2025 (Estimated)
RANI Rani Therapeutics	-$33.97M	-$0.99	N/A	N/A	N/A	N/A	-219.64%	-56.71%	8/5/2025 (Estimated)

Latest DFFN, RANI, ELYM, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFFN Diffusion Pharmaceuticals	N/A	10.71	10.71
ELYM Eliem Therapeutics	N/A	60.41	60.41
ONCY Oncolytics Biotech	N/A	2.99	2.99
RANI Rani Therapeutics	2.34	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFFN Diffusion Pharmaceuticals	9.95%
ELYM Eliem Therapeutics	69.76%
ONCY Oncolytics Biotech	6.82%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
DFFN Diffusion Pharmaceuticals	1.80%
ELYM Eliem Therapeutics	4.70%
ONCY Oncolytics Biotech	0.10%
RANI Rani Therapeutics	50.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFFN Diffusion Pharmaceuticals	13	2.04 million	2.00 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
ONCY Oncolytics Biotech	30	86.42 million	85.42 million	Not Optionable
RANI Rani Therapeutics	110	57.48 million	26.75 million	Optionable

DFFN, RANI, ELYM, and ONCY Headlines

Recent News About These Companies

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Average PT from Analysts

May 27 at 3:49 AM | americanbankingnews.com

Q3 Earnings Forecast for RANI Issued By Zacks Small Cap

May 23, 2025 | americanbankingnews.com

Brokers Offer Predictions for RANI Q2 Earnings

May 23, 2025 | americanbankingnews.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday

April 30, 2025 | marketbeat.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

April 1, 2025 | markets.businessinsider.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Rani Therapeutics Reports 2024 Financial Results and Updates

March 31, 2025 | tipranks.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025 | globenewswire.com

An Overview of Rani Therapeutics Hldgs's Earnings

March 28, 2025 | benzinga.com

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFFN, RANI, ELYM, and ONCY Company Descriptions

Diffusion Pharmaceuticals NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Eliem Therapeutics NASDAQ:ELYM

$1.22 -0.03 (-2.40%)

As of 05/29/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Oncolytics Biotech NASDAQ:ONCY

$0.34 -0.02 (-6.70%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 +0.02 (+4.71%)

As of 04:31 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Rani Therapeutics NASDAQ:RANI

$0.56 -0.02 (-2.62%)

As of 04:00 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time